2022
The thalamus and its subnuclei—a gateway to obsessive-compulsive disorder
Weeland CJ, Kasprzak S, de Joode NT, Abe Y, Alonso P, Ameis SH, Anticevic A, Arnold PD, Balachander S, Banaj N, Bargallo N, Batistuzzo MC, Benedetti F, Beucke JC, Bollettini I, Brecke V, Brem S, Cappi C, Cheng Y, Cho KIK, Costa DLC, Dallaspezia S, Denys D, Eng GK, Ferreira S, Feusner JD, Fontaine M, Fouche JP, Grazioplene RG, Gruner P, He M, Hirano Y, Hoexter MQ, Huyser C, Hu H, Jaspers-Fayer F, Kathmann N, Kaufmann C, Kim M, Koch K, Bin Kwak Y, Kwon JS, Lazaro L, Li CR, Lochner C, Marsh R, Martínez-Zalacaín I, Mataix-Cols D, Menchón JM, Minnuzi L, Moreira PS, Morgado P, Nakagawa A, Nakamae T, Narayanaswamy JC, Nurmi EL, Ortiz AE, Pariente JC, Piacentini J, Picó-Pérez M, Piras F, Piras F, Pittenger C, Reddy YCJ, Rodriguez-Manrique D, Sakai Y, Shimizu E, Shivakumar V, Simpson HB, Soreni N, Soriano-Mas C, Sousa N, Spalletta G, Stern ER, Stevens MC, Stewart SE, Szeszko PR, Takahashi J, Tanamatis T, Tang J, Thorsen AL, Tolin D, van der Werf YD, van Marle H, van Wingen GA, Vecchio D, Venkatasubramanian G, Walitza S, Wang J, Wang Z, Watanabe A, Wolters LH, Xu X, Yun JY, Zhao Q, White T, Thompson P, Stein D, van den Heuvel O, Vriend C. The thalamus and its subnuclei—a gateway to obsessive-compulsive disorder. Translational Psychiatry 2022, 12: 70. PMID: 35190533, PMCID: PMC8861046, DOI: 10.1038/s41398-022-01823-2.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderMagnetic resonance imagingThalamic volumeOCD patientsThalamic subregionsT1-weighted brain magnetic resonance imagingBrain magnetic resonance imagingClinical-level symptomsLarger thalamic volumesPediatric OCD patientsAdult OCD patientsSeparate multiple linear regression modelsVolumetric group differencesThalamus sizeMedicated patientsAdolescent patientsAnterior thalamusHealthy controlsSubregional volumesGeneral populationMedication statusMultiple comparison correctionPatientsResonance imagingIntracranial volume
2017
Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
Manza P, Amandola M, Tatineni V, Li CR, Leung HC. Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects. Npj Parkinson's Disease 2017, 3: 23. PMID: 28702504, PMCID: PMC5501877, DOI: 10.1038/s41531-017-0024-2.Peer-Reviewed Original ResearchDopamine replacement therapyEarly-stage Parkinson's diseaseDisease durationParkinson's diseaseDopaminergic medicationDopaminergic drugsDisease patientsResponse inhibitionCognitive functionDisease duration effectHallmark motor symptomsParkinson's disease durationShorter disease durationAdvanced Parkinson's diseaseParkinson's disease patientsRole of dopamineResponse inhibition deficitsMotor symptomsBasal gangliaHealthy controlsMedication statusMedicationsPatientsCognitive deficitsNeurodegenerative disorders